Immune Thrombocytopenia and JAK2V617F Positive Essential Thrombocythemia: Literature Review and Case Report

Table 1

MPN Ph(−) and ITP case reports.

Case number	1	2	3
Authors	Huang CE et al. [9]	Farhat et al. [10]	Sobas et al. [this report]
Sex	Female	Female	Female
ITP diagnosis	January 2009 (14 y.o.)	October 2001	July 1992 (45 y.o.)
ITP treatment	(1) DXM × 5; (2) Splenectomy (Aug. 2012)	(1) DXM × 4; (2) Igs (no data about doses)	(1) PD 1 mg/kg × 3 (1st and 2nd relapse); (2) After ET dgn: (i) 3rd ITP relapse: Igs 0,4 mg/kg × 5 days + AZT; (ii) 4th ITP relapse: PD + AZT
ET diagnosis	August 2012: highly probable	March 2001	January 2013
JAK2 mutation	Positive: 11% allele burden	Positive	Positive
BM biopsy	Not done (patient refused)	Compatible with ET (2001)	Compatible with ET (2013)
MPN – ITP latency	Not known	ITP diagnosed 8 months after ET diagnosis (in 1994 patient was diagnosed with TTP)	ET diagnosed after 21 years of follow-up
Splenomegaly	No	No	No
ET treatment	No data	(1) Aspirin and ANA for 2 months, no response; (2) HU	HU

Bone marrow (BM) biopsy, dexamethasone (DXM) 40 mg/day × 4 days, immunoglobulins (Igs), TTP (thrombotic thrombocytopenic purpura), ANA (anagrelide), HU (hydroxyurea), prednisone (PD), and azathioprine (AZT).